

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR

References are made to the announcement of Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”) dated January 2, 2026 (the “**Announcement**”) in relation to, among others, the resignation of Dr. Li Jia Kui (李嘉達) as an executive Director and general manager of the Company, the 2025 annual report of the Company published on April 27, 2026 (the “**Annual Report**”), the circular of the Company dated May 27, 2026 (the “**Circular**”) and the poll result announcement of the Company of even date. Unless otherwise specified, capitalized terms used in this announcement shall have the same meaning as defined in the Announcement, the Annual Report and the Circular.

As disclosed in the Announcement, Dr. Li has committed to continue performing his duties as an executive Director faithfully and diligently and his resignation shall only take effect upon the appointment of new executive Director to the Board by the general meeting of the Company. As disclosed in the Annual Report, the Board proposed to adjust the composition of the Board by appointing one employee representative Director to replace one executive Director position. Such adjustment has been put forward for approval to the annual general meeting of the Company held on June 18, 2026. Accordingly, Dr. Li's resignation as an executive Director will become effective immediately upon the appointment of the employee representative Director.

The Board hereby announces that the employee representatives' meeting of the Company was held on June 18, 2026, at which Ms. Yue Xin (岳鑫) (“**Ms. Yue**”) was elected as the employee representative Director of the second session of the Board upon consideration by the employee representatives present at the meeting, which will be effective from June 18, 2026, and her term of office shall be the same as that of the second session of the Board. She will be eligible for re-election after the expiration of her term of office.

Set out below is the biographical details of Ms. Yue:

Ms. Yue Xin (岳鑫), aged 32, was one of the Supervisors from November 2021 to June 2026, and was appointed as an employee representative Director with effect from June 18, 2026. She is primarily responsible for the administrative management of the Group and supervising the performance of duties by Directors and senior management.

Ms. Yue worked at Beijing Asia-East Bio-Pharmaceutical Co., Ltd. (北京亞東生物製藥有限公司) from October 2015 to February 2016. In January 2019, she joined the Group serving as an administrative assistant and successively got promoted to the positions of administrative specialist and head of administration in January 2020 and January 2022, respectively, primarily responsible for the administrative management affairs.

Ms. Yue graduated from China University of Political Science and Law (中國政法大學) in the PRC, majoring in law, in July 2018.

The Company will enter into a service agreement with Ms. Yue. The remuneration arrangement for Ms. Yue is as follows: she will not receive any remuneration for her directorship but will receive her remuneration under the labour contract signed with the Group and relevant policies of the Group. According to such labour contract, the annual remuneration of Ms. Yue is RMB130,000, which was determined with reference to Ms. Yue's qualification, experience and responsibilities.

Save as disclosed in this announcement, Ms. Yue (i) has not held any other major appointments or qualifications or directorships in other listed companies during the past three years preceding the date of this announcement; (ii) does not have any relationship with any Director, senior management, substantial or controlling Shareholder (having the meaning ascribed to it in the Listing Rules) of the Company; (iii) does not hold other positions with the Company or other members of the Group; and (iv) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571).

Save as disclosed in this announcement, the Board is not aware of any other matters in relation to Ms. Yue's election as an employee representative Director that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its welcome to Ms. Yue for her new position.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, June 18, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as an employee representative Director; and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.